Study of immune features in rare soft tissue sarcoma
Part of Cancer clinical trials.
This study looks at immune system “fingerprints” using tumor tissue from people with rare soft tissue sarcoma. It may help researchers understand what drives these cancers and guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older
- You have one of these rare sarcoma types: clear cell sarcoma, epithelioid sarcoma, PEComa, DSRCT, malignant solitary fibrous tumor, alveolar soft part sarcoma, epithelioid hemangioendothelioma, low-grade fibromyxoid sarcoma, or sclerosing epithelioid fibrosarcoma
- Your cancer is localized/locally advanced or has spread (metastatic)
- You must have tumor tissue saved from the initial diagnosis (before treatment), and it’s available for study
- You can take part in study activities and are able to give informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks if a blood test can detect DNA from soft tissue sarcomas. The goal is to see if circulating tumor DNA can help doctors monitor the disease and plan treatment.
This study looks at how soft tissue sarcoma clinical trials work and how patients do in them. It helps researchers understand the disease better, but does not test a new treatment.
This trial tests a new immune cell therapy (MASCT-I) combined with standard chemotherapy (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior chemotherapy or targeted therapy. The goal is to see if the combination works better than chemo alone.
This trial tests a new immunotherapy drug (envafolimab) combined with two chemotherapy drugs (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior treatment. The goal is to see if this combination is safe and effective.
This trial tests a personalized treatment plan for children and young adults with a type of soft tissue sarcoma (NRSTS). It uses a combination of surgery, targeted radiation, and two drugs (pazopanib and selinexor) to fight cancer while reducing side effects. The study is looking for people who have not been treated before for this sarcoma.
This trial tests a combination of immunotherapy (a treatment that helps your immune system attack cancer) and artificial intelligence (AI) technology as the first treatment for certain types of advanced soft tissue sarcoma. It aims to see if this approach can shrink tumors or stop them from growing better than current options.
Hear when a new Soft Tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.